Daphne Karydas

Daphne Karydas

Direktor/Vorstandsmitglied bei MINERALYS THERAPEUTICS, INC.

Vermögen: 195 300 $ am 31.05.2026

53 Jahre
Health Technology
Finance
Consumer Services

Profil

Daphne Karydas is the founder of Eucrates Biomedical Acquisition Corp., founded in 2020, and served as Independent Director from 2020 to 2023.
Ms. Karydas currently holds positions as Independent Director at Compass Pathways Plc since 2023, Independent Director at Mineralys Therapeutics, Inc. since 2023, and President & Chief Financial Officer at Flare Therapeutics, Inc. since 2021.
Former positions include Executive Director at JPMorgan Investment Management, Inc. from 2015 to 2017, Independent Director at Elicio Therapeutics, Inc., Independent Director at LogicBio Therapeutics, Inc. from 2020 to 2022, Portfolio Manager & Senior Analyst at The Boston Company Asset Management LLC from 2011 to 2014, Vice President at BNY Mellon Investment Adviser, Inc., Project Chemical Engineer at Merck & Co., Inc., Vice President at Goldman Sachs Asset Management LP in 2006, Chief Financial Officer at Syndax Pharmaceuticals, Inc. from 2020 to 2021, Associate at Goldman Sachs & Co. LLC.
from 2000 to 2003,.
and Senior VP-Corporate Financial Planning & Analysis at Allergan UC from 2018 to 2020.
Education includes undergraduate and graduate degrees from Massachusetts Institute of Technology, and an MBA from Harvard Business School conferred in 2000.

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
17.06.2026 6’200 ( 0.01% ) 195 300 $ 31.05.2026
27.05.2026 0 ( -.--% ) - $ 31.05.2026

Aktive Positionen von Daphne Karydas

UnternehmenPositionBeginn
MINERALYS THERAPEUTICS, INC. Direktor/Vorstandsmitglied 13.09.2023
COMPASS PATHWAYS PLC Direktor/Vorstandsmitglied 18.09.2023
Finanzdirektor/CFO 26.10.2021

Ehemalige bekannte Positionen von Daphne Karydas

UnternehmenPositionEnde
LOGICBIO THERAPEUTICS, INC. Direktor/Vorstandsmitglied 16.11.2022
SYNDAX PHARMACEUTICALS, INC. Finanzdirektor/CFO 22.10.2021
ALLERGAN PLC Public Communications Contact 10.12.2018
Analyst-Equity 01.04.2017
Analyst-Equity 01.12.2014
Sehen Sie sich die Erfahrung von Daphne Karydas im Detail an

Ausbildung von Daphne Karydas

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Beziehungen

93

Beziehungen ersten Grades

16

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Unternehmensverbindungen

Private Unternehmen16

Finance

Finance

Health Technology

Finance

Finance

Health Technology

Health Technology

Finance

Finance

Health Technology

Consumer Services

Health Technology

Health Technology

Finance

Health Technology

Health Technology

  1. Börse
  2. Insiders
  3. Daphne Karydas